Efficacy of five human melanocytic cell lines in experimental rabbit choroidal melanoma.
This study was undertaken to compare the ability of five uveal melanocytic cell lines to produce primary and metastatic uveal melanomas in immunosuppressed rabbits and to determine whether animal survival was improved by antibiotic administration. One hundred albino rabbit eyes, five groups of 20, were implanted in the suprachoroidal space with four melanoma cell lines (MKT-BR, OCM-1, 92-1 and SP 6.5) and one melanocytic line (UW-1). Rabbits were immunosuppressed with cyclosporin A (CsA) at a dosage of 15 mg/kg/day, decreased to 10 mg/kg/day after the fourth week. Prophylactic penicillin G, 10 to 2 x 10 IU, was administered intramuscularly at 5-day intervals. Animals were followed for 12 weeks and the ophthalmoscopic findings, weight and general well-being were recorded weekly. Autopsies were performed to study the eyes, liver and lungs under light microscopy. The mean global survival time in the groups was 43+/-4 days. Ophthalmoscopic intraocular tumours developed in 37% of the MKT-BR group, 50% of the OCM-1 group, 100% of the 92-1 group, 23% of the UW-1 group and 75% of the SP 6.5 group; histologically, tumours appeared in 36.8%, 45%, 100%, 58.8% and 100%, respectively. The 92-1 and SP 6.5 cell lines were associated with the most aggressive local behaviour. Lung metastases developed in the OCM-1 group (5%), 92-1 group (61.1%), UW-1 group (7.1%) and SP 6.5 group (42.1%), but were not present in the MKT-BR group. The 92-1 and SP 6.5 cell lines were the most efficient in local and metastatic tumour production. Prophylactic antibiotic administration did not improve animal survival.
López-Velasco
Rosario
R
Ocular Oncology & Pathology Unit, Instituto Universitario de Oftalmobiología Aplicada (IOBA), University of Valladolid, Valladolid, Spain.
Morilla-Grasa
Antonio
A
Saornil-Alvarez
María A
MA
Ordóñez
José L
JL
Blanco
Gonzalo
G
Rábano
Guillermo
G
Fernández
Nieves
N
Almaraz
Ana
A
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D045744:Cell Line, Tumor; D002830:Choroid Neoplasms / Q000473:pathology*; D016572:Cyclosporine / Q000494:pharmacology; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008544:Melanocytes / Q000473:pathology*; D008546:Melanoma, Experimental / Q000473:pathology*; D010400:Penicillin G / Q000494:pharmacology; D011817:Rabbits; D012878:Skin Neoplasms / Q000473:pathology; D015996:Survival Rate
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D010400:Penicillin G